Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EFEDRINA FRESENIUS KABI 3 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/EFEDRINA FRESENIUS KABI 3 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

EFEDRINA FRESENIUS KABI 3 MG/ML SOLUCION INYECTABLE

Fresenius Kabi España, S.A.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 17, 2024
Approval ID: b3c096a890ef967d
Company: Fresenius Kabi España, S.A.U.
Type: Standard

Approval Details

Approval Id: b3c096a890ef967d
Drug Cima Aemps Name: EFEDRINA FRESENIUS KABI 3 MG/ML SOLUCION INYECTABLE
Register Number: 89571
Holder Company Name: Fresenius Kabi España, S.A.U.
Marketing Company Name: Fresenius Kabi España, S.A.U.
Authorization Date: 2024-05-17
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 3 mg/ml
Route Of Administration: VÍA INTRAVENOSA
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Fresenius Kabi España, S.A.U.

Active Ingredients

EFEDRINA HIDROCLORURO

3 mg/ml

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 17, 2024

Approval ID

b3c096a890ef967d

Type

Standard

Back to CIMA-AEMPS Approvals